This drug is listed as a second-class protected species of traditional Chinese medicine!

According to data, as of June 2021, among the nearly 165,000 domestically produced drugs, only 265 were listed as protected varieties of traditional Chinese medicine, and 51 of them had reached the end of protection before the end of 2017.
Only 200 left
.
It can be seen from the above that the protected varieties of traditional Chinese medicines in China are scarce and have obvious competitive advantages; but it is worth noting that once they enter the protected varieties of traditional Chinese medicines, it also means that they will receive great attention and strong support from the state
.
Recently, the State Food and Drug Administration issued the "Announcement of Protected Varieties of Traditional Chinese Medicines (No.
7) (No.
7 of 2022)"
.
According to the announcement, according to the "Regulations on the Protection of Chinese Medicine Varieties", the State Food and Drug Administration approved Heilongjiang Zhenbaodao Pharmaceutical Co.
, Ltd.
's Xiaoer Resuqing Syrup as a second-class protected Chinese medicine.
The protected variety number is: ZYB2072022001, and the protection period is since Seven years from the announcement date
.
Zhenbaodao Pharmaceutical Co.
, Ltd.
is a comprehensive large-scale health pharmaceutical enterprise whose business spans the pharmaceutical industry, traditional Chinese medicine industry, and pharmaceutical business.
It is also one of the giants of traditional Chinese medicine pharmaceutical companies
.
Over the years, it has always adhered to the core of drug research and development, production and sales, and gradually enriched the industrial chain structure; it also attaches great importance to the construction of the research and development system and the improvement of research and development capabilities.
At present, it has gradually established a Beijing research and development center as the core, covering R&D system of R&D bases in Shanghai and Harbin
.
It is understood that the innovative research and development of traditional Chinese medicine products has actually been the pillar industry of Zhenbaodao Pharmaceutical.
The company has long adhered to the innovative research and development of traditional Chinese medicine varieties.
Through continuous exploration and practice, it has developed Xuesaitong for injection, Xueshuantong capsule, injection A large number of drugs are used to treat cardiovascular and cerebrovascular, bone injury, and respiratory system diseases, such as bone peptide, Shuxuening injection, and compound Qinlan oral liquid
.
Among them, Xiaoer Resuqing Syrup, which is listed as the second-class protected variety, is also the modern Chinese medicine variety that Zhenbaodao Pharmaceutical has long adhered to the innovative research and development of traditional Chinese medicine varieties, and has developed through continuous exploration and practice
.
The industry believes that this time, Xiaoer Resuqing syrup has become a second-class protected variety of traditional Chinese medicine, which will further promote its future sales and development
.
In recent years, in fact, my country has been increasing the protection of traditional Chinese medicine varieties, and at the same time, the related traditional Chinese medicine protection system has been continuously improved and perfected.

.
In September 2018, the State Council issued and revised the "Regulations on the Protection of Varieties of Traditional Chinese Medicine", which clearly stated that it will play a role in protecting traditional Chinese medicine varieties such as innovative traditional Chinese medicines, new improved traditional Chinese medicines, and ancient classic traditional Chinese medicine compound preparations
.
In addition, in December 2020, the state issued the "Opinions on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicine", which once again made it clear that it is necessary to increase the protection of traditional Chinese medicine varieties
.
In this context, the industry believes that with the continuous implementation of the protection system for traditional Chinese medicine varieties in the future, it will further promote the significant improvement of the quality of traditional Chinese medicine varieties, protect the legitimate rights and interests of production enterprises, and effectively curb low-level duplication of traditional Chinese medicine varieties.
Unreasonable utilization of resources, accelerate the adjustment of the structure of traditional Chinese medicine products, promote the intensification and scale of traditional Chinese medicine production, and promote the healthy development of traditional Chinese medicine
.